Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with longer PFS, suggesting T-cell composition may serve as a biomarker to ...
Immunitas Therapeutics Inc. has revealed preclinical data supporting development of its potentially first-in-class, fully human anti-CD161 antibody, IMT-380. CD161-expressing T-cell subsets have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results